The rare disease therapy was developed by Modis Therapeutics. This company is based on Columbia University research. Modis Therapeutics was formed through a collaboration with academic experts in mitochondrial biology to develop disease-modifying therapies for rare genetic diseases. The company completed a series A financing with investments from F-Prime Capital Partners, OrbiMed, Aceras Life Sciences, and Osage University Partners. The company has assembled a management team with deep experience in the development of high-impact products for serious diseases at leading biotech and pharmaceutical companies. Modis is a dedicated team, passionate about bringing novel therapies to patients with uncommon diseases.